ESTRO 2025 - Abstract Book

S1797

Clinical – Upper GI

ESTRO 2025

References: [1] Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, Koong AC, Holliday EB, Taniguchi CM, Katz MHG, Tamm EP, Wolff RA, Overman MJ, Patel S, Kim MP, Tzeng CD, Ikoma N, Bhutani MS, Koay EJ. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Jan 11;33:66-69. doi: 10.1016/j.ctro.2021.12.012. PMID: 35097226; PMCID: PMC8783106.

2445

Digital Poster Concurrent Chemoradiation Outperforms Chemotherapy Alone in the Treatment of Unresectable Biliary Tract Cancers: A Meta-analysis. Ludovica Forlani 1 , Silvia Bisello 2 , Claudio Malizia 3 , Erika Galietta 1 , Filippo Mammini 1 , Federica Medici 1 , Filippo Candoli 4 , Patrick Duhanxhiu 4 , Deborah Barravecchia 4 , Vittoria Rosetti 4 , Gian Carlo Mattiucci 5,6 , Francesco Cellini 5,6 , Andrea Palloni 7 , Luca Tagliaferri 8 , Gabriella Macchia 9 , Francesco Deodato 8 , Savino Cilla 10 , Giovanni Brandi 7 , Alessandra Arcelli 4 , Alessio G Morganti 4 1 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Bologna University, Bologna, Italy. 2 Radiation Oncology, AOU delle Marche, Ancona, Italy. 3 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 4 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 5 Dipartimento Universitario Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy. 6 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. 7 Medical Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. 8 Dipartimento di Diagnostica per Immagini, U.O.C. Radioterapia Oncologica, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. 9 Radiation Oncology Unit, Gemelli Molise Hospital-Università Cattolica del Sacro Cuore, Campobasso, Italy. 10 Medical Physics Unit, Responsible Research Hospital, Gemelli Molise Hospital, Campobasso, Italy Purpose/Objective: Biliary tract cancers (BTC) are rare and aggressive neoplasms. The management of the locally advanced or unresectable BTC is mainly based on chemotherapy (CHT). Chemoradiation (CRT) may represent an alternative treatment. Aim of this study is to compare the current knowledge between combined CRT or CHT alone for primary or recurrent unresectable BTC. Material/Methods: Papers were searched on PubMed, Scopus, and Cochrane Library. Prospective or retrospective trials reporting a comparison between concurrent CRT or CHT alone for unresectable non-metastatic, primary or recurrent BTC were included. Only English-written papers, published from January 2010 to June 2022 were considered. Results: Four papers were included in the analysis, with a total of 1578 patients treated with concurrent CRT, and 4521 treated with CHT alone. All papers focused on primary unresectable BTC. Three papers considered 100.0% patients with intrahepatic cholangiocarcinoma, one paper 100.0% patients with gallbladder cancer. Median follow up was 10.1 months (range 9.0-11.3 months). Median overall survival (OS) for CRT group was 12.9 months (range 12.7 13.6). Median overall survival (OS) for CHT group was 10.5 months (range 7.8 – 12.0). A meta-analysis comparing outcomes of concurrent CRT versus CHT showed a significant advantage in favour of CRT (HR 0.70, 0.59-0.82, 95% CI).